Related references
Note: Only part of the references are listed.TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+myeloma cells
Vijay Ramakrishnan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
V. Ramakrishnan et al.
ONCOGENE (2010)
De novo Discovery of a gamma-Secretase Inhibitor Response Signature Using a Novel In vivo Breast Tumor Model
James W. Watters et al.
CANCER RESEARCH (2009)
Inhibition of NOTCH Signaling by Gamma Secretase Inhibitor Engages the RB Pathway and Elicits Cell Cycle Exit in T-Cell Acute Lymphoblastic Leukemia Cells
Sudhir S. Rao et al.
CANCER RESEARCH (2009)
Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes
Chelsea C. Pinnix et al.
CANCER RESEARCH (2009)
Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma
Suk-young Lee et al.
CANCER SCIENCE (2009)
Notch Signaling: The Core Pathway and Its Posttranslational Regulation
Mark E. Fortini
DEVELOPMENTAL CELL (2009)
Inhibition of γ-Secretase Activity Inhibits Tumor Progression in a Mouse Model of Pancreatic Ductal Adenocarcinoma
Ruben Plentz et al.
GASTROENTEROLOGY (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Notch signaling in leukemia
Jon C. Aster et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Notch inhibition blocks multiple myeloma cell-induced osteoclast activation
R. Schwarzer et al.
LEUKEMIA (2008)
Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy
Yulia Nefedova et al.
BLOOD (2008)
γ-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers
Jun Konishi et al.
CANCER RESEARCH (2007)
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia
Steven M. Chan et al.
BLOOD (2007)
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis
Irene Noguera-Troise et al.
NATURE (2006)
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth
Teresa Palomero et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
Stephen Breit et al.
BLOOD (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies
PA Zweidler-McKay et al.
BLOOD (2005)
Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression
K Balint et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function
NS Patel et al.
CANCER RESEARCH (2005)
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
S Kumar et al.
LEUKEMIA (2005)
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
F Jundt et al.
BLOOD (2004)
Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation
GT Wong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
S Kumar et al.
BLOOD (2004)
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma
N Raje et al.
BLOOD (2004)
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia
AP Weng et al.
SCIENCE (2004)
JAGGED1 expression is associated with prostate cancer metastasis and recurrence
S Santagata et al.
CANCER RESEARCH (2004)
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Y Nefedova et al.
BLOOD (2004)
Expression of VEGF and its receptors by myeloma cells
S Kumar et al.
LEUKEMIA (2003)
Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells
TH Landowski et al.
ONCOGENE (2003)
HES and HERP families: Multiple effectors of the Notch signaling pathway
T Iso et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2003)
Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma
F Jundt et al.
BLOOD (2002)
Notch-1 regulates NF-κB activity in hemopoietic progenitor cells
PY Cheng et al.
JOURNAL OF IMMUNOLOGY (2001)
Induction of cyclin D1 transcription and CDK2 activity by Notchic:: Implication for cell cycle disruption in transformation by Notchic
C Ronchini et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation
A Rangarajan et al.
EMBO JOURNAL (2001)
Notch signaling: From the outside in
JS Mumm et al.
DEVELOPMENTAL BIOLOGY (2000)
A novel proteolytic cleavage involved in Notch signaling:: The role of the disintegrin-metalloprotease TACE
C Brou et al.
MOLECULAR CELL (2000)
A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1
JS Mumm et al.
MOLECULAR CELL (2000)
Share Paper
